News
Seminar

Damien GREGOIRE

Institut de Génétique Moléculaire de Montpellier (IGMM) CNRS-UMR 5535

Route de Mende, Montpellier

"Oncogenic cooperations : investigating inter and intra-tumoral heterogeneity in hepatocellular carcinoma"

Dr. Gregoire and his collaborators develop innovative murine models to study liver cancer heterogenity. They explore how the genetic composition of hepatocarcinoma influences their development, their interaction with the microenvironment, and their response to therapies.

Mickaël Le Clech, PhD

Business Developer

ENSCM-USCBF-CN

"Discover your drug candidate with ChemBioFrance and the French National Chemical Library"

host : Eric JULIEN (IRCM)

Emmanuelle HUILLARD

Equipe "Génétique et développement des tumeurs cérébrales"

Institut du Cerveau / ICM

Hôpital de la Pitié-Salpêtrière

CNRS UMR7225-Inserm U1127-Sorbonne Université

"Mechanisms of tumor initiation in IDH-mutant gliomas"

contact : Lucille STUANI (IRCM)

Borhane GUEZGUEZ

Department Hematology and Medical Oncology, University Medical Center Mainz, Germany

"Advancing Cancer Therapy in Leukemia : The Intersection of Epigenetics, Inflammation and Tumor Microenvironment"

host : Alexandre Djiane (IRCM)

Eileen PARKES

Associate Professor,

Innate tumor Immunology laboratory

Oxford University, England

"Targeting immunosuppression in Chromosomally unstable cancers"

Dr Eileen Parkes is an early phase medical oncologist and associate professor at the University of Oxford. She completed her medical oncology training and PhD at Queens University Belfast before moving to Oxford in 2019. She leads early phase studies of novel IO, including STING agonsits, and is lead for Oxford Experimental Cancer Medicine Centre, focusing on translational research. Her lab team studies the tumour microenvironment of chromosomally unstable cancers, with a particular focus on cGAS-STING signalling, intending to identify novel therapeutic strategies for chromosomally unstable cancers including oesophageal adenocarcinomas.

host: Julien Faget (IRCM)

Gilles PAGES

Université Cote d'Azur,

Institut de Recherche Cancer et Vieillissement de Nice (IRCAN)

UMR CNRS 7284/U Inserm 1081

"From the discovery of mechanisms of resistance to conventional therapies to the establishment of innovative treatments for metastatic kidney cancers"

hôte : Alexandre DAVID (IRCM)

Bassam Janji, PhD

Group Leader, Tumor Immunotherapy and Microenvironment

Luxembourg Institute of Health, Department of Cancer Research

"Breaking the Shield: Innovative Approaches to Overcome the Immunosuppressive Tumor Microenvironment and Improve Cancer Immunotherapy."

contact : Andrei Turtoi (IRCM)

Raphael J. Morscher

Pediatric Cancer Metabolism Laboratory, Children's Research Center,

University of Zurich, 8032 Zurich, Suisse

"Reprogramming neuroblastoma translation by diet-enhanced polyamine depletion"

hôte : Alexandre DAVID (IRCM)

Jihane BASBOUS, PhD

Institut de Génétique Humaine (IGH), CNRS UMR 9002

Université de Montpellier, France

"Compartmentalization of the DNA damage response: Mechanisms and functions"

Our research investigates the molecular mechanisms and functions of protein compartmentalization in response to DNA damage and repair. Focusing on two critical scaffolding proteins, TopBP1 and SLX4, we have elucidated how their assembly into nanocondensate clusters following DNA damage activates specific signalling pathways. Our research aims to demonstrate how DNA repair foci, functioning as biomolecular condensates, link molecular mechanisms to cellular physiological functions. Our work offers valuable insights into the regulatory mechanisms of the DNA damage response compartmentalization and opens new avenues for developing innovative cancer management strategies.